UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2022

Commission File Number: 001-37993

 

 

OBSEVA SA

(Translation of registrant’s name into English)

 

 

Chemin des Aulx, 12

1228 Plan-les-Ouates

Geneva, Switzerland

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:   ☒    Form 20-F  ☐    Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


INCORPORATION BY REFERENCE

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3, as amended (No. 333-221462, 333-233069, 333-260974 and 333-262820) of ObsEva SA (including any prospectuses forming a part of such registration statements) and the registration statements on Form S-8 (Registration No. 333-216170, 333-231629 and 333-249457 and 333-263234) of ObsEva SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXPLANATORY NOTE

On May 27, 2022, ObsEva SA (the “Company”) entered into a waiver and amendment agreement (the “Amendment Agreement”) with certain funds and accounts managed by JGB Management, Inc. (“JGB”), in relation to the Company’s amended and restated securities purchase agreement (the “Securities Purchase Agreement”), deemed dated as of October 12, 2021, with JGB, which is structured to provide up to $135 million in borrowing capacity, available in nine tranches. The third tranche under the Securities Purchase Agreement was due to be funded on May 25, 2022. However, the tranche has not been funded as a result of the Company not meeting the funding condition that its volume-weighted average share price would not trade below $3.00 per share for five or more trading days during the 30 days prior to the funding date for the third tranche. Pursuant to the Amendment Agreement, JGB has agreed to waive its right to terminate its obligation to fund future tranches under the Securities Purchase Agreement, which JGB would be entitled to as a result of the Company’s failure to meet the share price funding condition for the third tranche. In exchange, the Company has agreed to further restrictions on the existing account control agreement in favor of JGB, which secures the Securities Purchase Agreement, to establish a “blocked” account control agreement with respect to the applicable bank account. The further restrictions will be implemented by amending the account assignment agreement and control agreement entered into in connection with the Securities Purchase Agreement, with such amendments to be executed within 20 days from the date hereof. The Company and JGB have also agreed to certain amendments regarding minimum cash reporting obligations with respect to the applicable bank account. JGB also retains the right, at its sole option, to fund the third tranche at any time prior to the fourth tranche funding date, which is August 23, 2022. Except as provided herein and in the Amendment Agreement, the terms of the Securities Purchase Agreement, including with respect to future tranches and the ancillary agreements entered into in connection therewith, remained unchanged.

A copy of the Amendment Agreement is attached as Exhibit 99.2 hereto, and is incorporated herein by reference. The foregoing description of the Amendment Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.

On May 27, 2022, the Company issued a press release announcing that it had entered into the Amendment Agreement. A copy of the press release is filed as Exhibit 99.1 to this Form 6-K and incorporated by reference herein.

FORWARD-LOOKING STATEMENTS

Statements in this Form 6-K that are not strictly historical in nature, including but not limited to, statements regarding the Company’s expectations with respect to the timing and availability of borrowing under the Securities Purchase Agreement. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including market risks and uncertainties and risks relating to the satisfaction of funding conditions for each tranche, and other risks and uncertainties that are described in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with SEC on March 10, 2022 and in the Report on Form 6-K filed with the SEC on May 17, 2022 and other filings the Company makes with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof, except as required by law.


EXHIBIT INDEX

 

Exhibit
No.
  

Description

99.1    Press Release dated May 27, 2022.
99.2    Amendment Agreement, dated as of May 27, 2022, by and among the Company, the Subsidiary Guarantors and the Holder.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ObsEva SA

Date: May 27, 2022

 

By:

 

/s/ Brian O’Callaghan

   

Name

 

Brian O’Callaghan

   

Title:

 

Chief Executive Officer

Exhibit 99.1

 

LOGO

ObsEva Announces Corporate Updates

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

GENEVA, Switzerland – May 27, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc. (JGB), which is structured to provide up to $135 million in borrowing capacity, available in nine tranches.

The third tranche under the Securities Purchase Agreement was due to be funded on May 25, 2022. However, the tranche has not been funded as a result of ObsEva not meeting the funding condition that its volume-weighted average share price would not trade below $3.00 per share for five or more trading days during the 30 days prior to the funding date for the third tranche. Pursuant to the Amendment Agreement, JGB has agreed to waive its right to terminate its obligation to fund future tranches under the Securities Purchase Agreement, which JGB would be entitled to as a result of the failure to meet the share price funding condition for the third tranche. In exchange, ObsEva has agreed to further restrictions on the existing account control agreement in favor of JGB, which secures the Securities Purchase Agreement. JGB also retains the right, at its sole option, to fund the third tranche at any time prior to the fourth tranche funding date, which is August 23, 2022. Except as noted, the terms of the Securities Purchase Agreement and ancillary agreements, including with respect to future tranches, remained unchanged. Further information with respect to the amendment to the convertible note financing agreement will be provided in a Form 6-K filed by ObsEva with the Securities and Exchange Commission on May 27, 2022.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward Looking Statements of ObsEva SA

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include statements regarding the potential to raise funds in the future, including the availability of future tranches under the Securities Purchase Agreement, and the use of such fund from future fundraisings or from the financing agreement with JGB. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include the ability of


LOGO

the ObsEva to meet the conditions required to fund future tranches under the Securities Purchase Agreement, uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the ongoing novel coronavirus outbreak and other geopolitical events, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with Securities and Exchange Commission (SEC) on March 10, 2022, in the Report on Form 6-K filed with the SEC on May 17, 2022 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and, except as required by law, ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Office contact

Shauna Dillon

shauna.dillon@obseva.ch

+41 22 552 1550

Investor Contact

Katja Bührer

Katja.buhrer@obseva.com

+1 (917) 969-3438

Exhibit 99.2

WAIVER AND AMENDMENT AGREEMENT

This Wavier and Amendment Agreement (the “Agreement”), dated as of May 27, 2022, is made by and between JGB (Cayman) Port Ellen Ltd., in its capacity as Holder, ObsEva SA, a Swiss stock corporation (the “Company”) and each of ObsEva USA Inc., ObsEva Ireland Ltd., and ObsEva Europe B.V., as subsidiary guarantors (collectively, the “Subsidiary Guarantors”, and together with the Company, the “Company Parties”).

WHEREAS, the Holder and the Company are parties to that certain Amended and Restated Securities Purchase Agreement, deemed dated as of October 12, 2021 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time in accordance with its provisions, the “SPA”), whereby, among other things, (i) the Company has issued to the Holder, and the Holder has acquired from the Company, that certain Senior Secured Convertible Note due October 12, 2024, in the aggregate original principal amount of $31,496,063 (the “Initial Tranche Note”), and that certain Senior Secured Convertible Note due January 28, 2025, in the aggregate original principal amount of $10,500,000 (the “First Mandatory Tranche Note”), (ii) each of the Subsidiary Guarantors have executed that certain Corporate Guaranty, dated October 12, 2021, pursuant to which each such Subsidiary Guarantor guaranteed, among other things, payment of the Obligations (as defined in such Corporate Guaranty), and (iii) Company and Holder, as assignee and security agent, have entered into that certain Account Assignment Agreement, dated as of October 12, 2021 (the “Account Assignment Agreement”);

WHEREAS, pursuant to the SPA, the Holder and the Company have agreed that the Company will, subject to the terms and conditions set forth in the SPA, on May 25, 2022 (the “Second Mandatory Tranche”), August 23, 2022, and November 21, 2022, issue and sell to the Purchasers, as defined in the SPA, additional aggregate principal amounts of Notes and numbers of Warrants as set forth in Section 2.2 of the SPA;

WHEREAS, as set forth in Section 2.5(c)(vii) of the SPA, as a condition for Holder’s purchase obligations with respect to the Second Mandatory Tranche, the VWAP of the Company’s common stock could not be below $3.00 per share (subject to appropriate adjustment for stock splits, stock dividends, reverse stock splits, share combinations and similar events) for five (5) or more Trading Days during the applicable Measurement Period (the “Share Price Funding Condition”);

WHEREAS, the parties acknowledge and agree that the Share Price Funding Condition has not been met with respect to the Second Mandatory Tranche (the “Second Mandatory Tranche Share Price Funding Condition Failure”), and as a result, the Company has not sold, and the Holder has not purchased (and is not required to purchase), Notes with respect to the Second Mandatory Tranche (the “Second Mandatory Tranche Notes”), and the second Mandatory Tranche Closing Date has not occurred as of the date hereof; and

WHEREAS, the parties now desire to enter into this Agreement to, among other things, waive Holder’s right to terminate its purchase obligations with respect to future Tranches due to the Second Mandatory Tranche Share Price Funding Condition Failure and to amend the Notes and Account Assignment Agreement pursuant to the terms and conditions set forth herein.


NOW, THEREFORE, in consideration of the premises set forth above and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

  1.

Definitions. Capitalized terms used and not defined in this Agreement shall have the respective meanings given such terms in the SPA.

 

  2.

Certain Acknowledgements and Agreements.

 

  a.

Waiver of Second Mandatory Tranche Share Price Funding Condition Failure. Subject to the occurrence of the Effective Date (as defined below), the Holder waives and forever releases for all purposes any right to terminate the SPA (including pursuant to Section 5.1(iii) of the SPA), solely with respect to Holder’s obligation to purchase additional Securities with respect to any future Mandatory Tranche Closing or Optional Tranche Closing, due to the Second Mandatory Tranche Share Price Funding Condition Failure. For the avoidance of doubt, the waiver and release provided for in this Section 2(a) shall apply solely to the Second Mandatory Tranche Share Price Funding Condition Failure and shall not waive any right to termination by the Holder based on a failure of any funding condition for any future Mandatory Tranche Closing or Optional Tranche Closing as provided in the SPA.

 

  b.

Account Assignment Agreement. Each of the Holder and the Company Parties agree to enter into, not later than 20 days after the date of this Agreement, (x) an amendment to the Account Assignment Agreement (the “Amended Account Assignment Agreement”) and (y) an amendment (the “Control Agreement Amendment”) to the Control Agreement (the “Control Agreement”), dated October 12, 2021, by and among, the Company, the Holder and UBS Switzerland AG (the “Custodian”), in each case, reasonably acceptable to the Holder in form and substance, to modify the terms and conditions applicable to the Bank Account (as defined in the Account Assignment Agreement) to establish a “blocked” account control agreement with respect to the Bank Account wherein the Custodian shall only accept disposition instructions from the Holders, without further consent from any of the Company Parties. For clarity, the Company Parties shall cause the Custodian to execute and deliver the Control Agreement Amendment not later than 20 days after the date of this Agreement.

 

  c.

Senior Secured Convertible Notes. Subject to the occurrence of the Effective Date, Each of the Holder and the Company Parties acknowledge and agree that Section 6(b) of the Notes, including each of the Initial Tranche Note and First Mandatory Tranche Note, shall be amended and restated in its entirety and replaced with the following:

“(b) Minimum Cash. Until the later of: (i) less than Ten Million Dollars ($10,000,000) aggregate principal amount of Notes sold pursuant to the Purchase Agreement are outstanding, and (ii) until November 21, 2022, the Company shall at all times maintain


on deposit in bank accounts subject to Account Control Agreements, an average three-day cash balance of not less than the Minimum Cash Amount then in effect. The Company shall cause the Agent to have view only access to its deposit account(s) subject to an Account Control Agreement in order to permit Agent, at its option, to monitor the Company’s cash balances in such account(s) and compliance with this Section 6(b).”

 

  d.

The Holder has fully and timely performed all of its obligations and duties in compliance with the Transaction Documents and applicable law, and has acted reasonably, in good faith, and appropriately under the circumstances.

 

  e.

In further consideration of the Holder’s execution of this Agreement, each of the Company Parties, on behalf of itself and its successors, assigns, parents, subsidiaries, affiliates, officers, directors, employees, agents and attorneys, hereby forever, fully, unconditionally and irrevocably waives and releases the Holder and its successors, assigns, parents, subsidiaries, affiliates, officers, directors, employees, attorneys and agents (collectively, the “Releasees”) from any and all claims, liabilities, obligations, debts, causes of action (whether at law or in equity or otherwise), defenses, counterclaims, setoffs, of any kind, whether known or unknown, whether liquidated or unliquidated, matured or unmatured, fixed or contingent, directly or indirectly arising out of, connected with, resulting from or related to any act or omission by the Holder or any other Releasee, prior to the date hereof, with respect to the Transaction Documents (collectively, the “Claims”). Each Company Party further agrees that none of them shall commence, institute, or prosecute any lawsuit, action or other proceeding, whether judicial, administrative or otherwise, to prosecute, collect or enforce any Claim. Notwithstanding anything to the contrary set forth above, the release provided for in this Section 2(c) shall not apply to the obligations of the Releasees provided for in this Agreement.

 

  f.

The Company agrees that, notwithstanding anything contained herein to the contrary, on or prior to August 23, 2022, Holder shall be entitled to purchase, at its sole election, in accordance with the terms of the SPA, the Second Mandatory Tranche Notes from the Company by providing two (2) Trading Days prior written notice to the Company of the exercise of such option, and upon receipt of such notice from the Holder, the Company agrees to issue and sell the Second Mandatory Tranche Notes to the Holder within two (2) Trading Days of receipt of such notice.

 

  3.

Certain Reaffirmations and Reconfirmation of Security Interest and Subsidiary Guaranty

 

  a.

The SPA, the Initial Tranche Note, the First Mandatory Tranche Note, the Account Assignment Agreement and the other Transaction Documents are legal, valid, binding and enforceable against the Holder and the Company and the Subsidiary Guarantors in accordance with their respective terms. The terms of the Transaction Documents remain unchanged, except as modified pursuant to this Agreement.


  b.

The Company’s and each Subsidiary Guarantor’s respective obligations under the Transaction Documents are not subject to any setoff, deduction, claim, counterclaim or defenses of any kind or character whatsoever. As of the date hereof, the amount of cash in the bank accounts described in section 6(b) of the Notes exceeds $33,250,000.

 

  c.

Holder and Agent have valid, enforceable and perfected security interests in and liens on the Account Balances (as defined in the Account Assignment Agreement) and any other Collateral (as defined in the Agency Agreement), as to which there are no setoffs, deductions, claims, counterclaims, or defenses of any kind or character whatsoever.

 

  d.

Nothing herein shall impair or limit the continuation of the liens and security interests granted to the Holder and/or the Agent under the Account Assignment Agreement, the Account Control Agreement or any of the other Security Documents, which liens are continued in full force and effect pursuant to and as provided therein and herein and the Secured Obligations (as defined in the Account Assignment Agreement) shall extend to any and all obligations of the Company under or in connection with this Agreement and the SPA. The Company and each Subsidiary Guarantor agrees that any reference to the Initial Tranche Note, First Mandatory Tranche Note or the “Senior Secured Convertible Notes” (as applicable) in any Security Document includes the Initial Tranche Note, First Mandatory Tranche Note or the “Senior Secured Convertible Notes”, respectively (as applicable), as amended pursuant to this Agreement and any reference to the Account Assignment Agreement in any Security Document means the Amended Account Assignment Agreement. The Company and each Subsidiary Guarantor acknowledges the continuing existence and priority of all liens and security interests granted, conveyed, and assigned pursuant to the Security Documents in accordance with the terms thereof and hereof notwithstanding the coming into effect of the Amended Account Assignment Agreement, and agrees to perform such acts and duly authorize, execute, acknowledge, deliver, file, and record such additional documents and certificates as the Holder or the Agent request in order to perfect, preserve, and protect such liens and security interests.

 

  e.

Each Subsidiary Guarantor acknowledges this Agreement and ratifies and confirms that the Corporate Guaranty executed by such Subsidiary Guarantor is not released, diminished, impaired, reduced, or otherwise adversely affected by this Agreement and continues to guarantee and assure the full payment and performance of all present and future obligations under the Notes (including each of the Initial Tranche Note and First Mandatory Tranche Note as amended by this Agreement) and the other Transaction Documents.

 

  f.

The Holder and the Agent have fully and timely performed all of their obligations and duties in compliance with the Transaction Documents and applicable law, and have acted reasonably, in good faith, and appropriately under the circumstances.


  4.

Representations and Warranties of the Company Parties. Each of the Company Parties represents and warrants, severally and jointly, to the Holder that:

 

  a.

Authorization; Enforcement. Each of the Company Parties has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement, the Control Agreement Amendment and the Amended Account Assignment Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement, the Control Agreement Amendment and the Amended Account Assignment Agreement by the respective Company Parties and the consummation by each of them of the transactions contemplated hereby and thereby have been (or will be on the Effective Date) duly authorized by all necessary action on the part of each such Company Party and no further action is required by any Company Party in connection herewith or therewith other than in connection with the Required Approvals. This Agreement, the Control Agreement Amendment and the Amended Account Assignment Agreement have been (or upon delivery will have been), in the case of this Agreement, duly executed by each Company Party or, in the case of the Amended Account Assignment Agreement and the Control Agreement Amendment, duly executed by the Company, and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of each such Company Party enforceable against each such Company Party in accordance with its terms, except as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally.

 

  b.

No Conflicts. The execution, delivery and performance by the Company Parties of this Agreement and, in the case of the Company, the Control Agreement Amendment and the Amended Account Assignment Agreement, and the consummation by each of them of the transactions contemplated hereby and thereby, do not and will not: (i) conflict with or violate any provision of such Company Party’s certificate or articles of incorporation, bylaws or other organizational or charter documents, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of any Company Party, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, securities purchase agreement, debt or other instrument (evidencing Indebtedness of any Company Party or otherwise) or other understanding to which any Company Party is a party or by which any property or asset of any Company Party is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or Governmental Authority to which a Company Party is subject (including federal and state securities laws and regulations), or by which any property or asset of a Company Party is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not reasonably be expected to result in a Material Adverse Effect.


  c.

Absence of Defaults. No Event of Default has occurred or is continuing, and each Company Party has complied in all material respects with its respective obligations under the Transaction Documents.

 

  d.

Solvency. Based on the consolidated financial condition of the Company as of the date hereof, after giving effect to the transactions contemplated hereunder: (i) the fair saleable value of the Company’s assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur Indebtedness beyond its ability to pay such Indebtedness as it matures (taking into account the timing and amounts of cash to be payable on or in respect of its Indebtedness).

 

  e.

Representations and Warranties in Transaction Documents. The representations and warranties set forth in each Transaction Document shall, in each case, be true and correct in all respects with the same effect as made on the date of this Agreement (unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date), in each case, except as set forth in any SEC Report filed by the Company with the Commission subsequent to October 12, 2021.

 

  f.

Rule 144. For the avoidance of doubt, and to the extent applicable, the Company Parties acknowledge and agree that the holding period for purposes of Rule 144 under the U.S. Securities Act of 1933, as amended, of each of the Initial Tranche Note and the First Mandatory Tranche Note is not affected by this Agreement or the transactions contemplated hereby and tacks back to October 12, 2021, in the case of the Initial Tranche Note, and January 28, 2022, in the case of the First Mandatory Tranche Note.

 

  5.

Representations and Warranties of Holder. Holder represents and warrants to the Company Parties that:

 

  a.

Authorization; Enforcement. Holder has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement, the Control Agreement Amendment and the Amended Account Assignment Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement, the Control Agreement Amendment and the Amended Account Assignment Agreement by the Holder and the consummation by Holder of the transactions contemplated hereby and thereby


  have been duly authorized by all necessary action on the part of Holder and no further action is required by Holder in connection herewith. This Agreement, the Control Agreement Amendment and the Amended Account Assignment Agreement has been (or upon delivery will have been) duly executed by Holder and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of Holder enforceable against Holder in accordance with its terms.

 

  6.

Deliveries and Other Conditions. In connection with the transactions contemplated by this Agreement, the Company Parties shall deliver to the Holder the following:

 

  a.

on the date of this Agreement, a duly executed PDF copy of this Agreement (and, promptly after the date hereof, “wet ink” originals of Company Parties’ signature pages to this Agreement);

 

  b.

on the date of this Agreement, satisfactory evidence that all corporate and other proceedings that are necessary in connection with the Amendment Documents have been taken;

 

  c.

the Company will reimburse the Holder’s legal fees in connection with this Agreement in the amount equal $5,000.

 

  d.

such other documents, confirmations, agreements or other instruments reasonably requested by Holder.

 

  7.

Effective Date. Not later than 20 days after the date of this Agreement the Company and the Holder shall execute and deliver the Amended Account Assignment Agreement and the Control Agreement Amendment, and in the case of the Control Agreement Amendment, cause the Custodian to execute and deliver to the Control Agreement Amendment. The date upon which the Amended Account Assignment Agreement and the Control Agreement Amendment have been executed and delivered by the Company and the Custodian, as applicable, shall be deemed the “Effective Date.” If the Effective Date has not occurred by the date that is 20 days after the date of this Agreement, then the provisions of Sections 2(a) and 2(c) of this Agreement shall not come into effect, have no force and effect and shall be void ab initio.

 

  8.

Transaction Documents. Each Amendment Document is a Transaction Document. The Amendment Documents, together with the other Transaction Documents, are the entire agreement among the parties with respect to the subject matter hereof.

 

  9.

No Modification. Except as set forth in the Amendment Documents, nothing shall be deemed or construed to amend, supplement or modify the Transaction Documents or otherwise affect the rights, remedies and/or obligations of any party thereto, all of which remain in full force and effect.

 

  10.

Successors and Assigns; Survival. This Agreement shall inure to the benefit of and be binding upon each of the parties hereto, and each of their respective successors and assigns. The representations and warranties of the Company Parties and the Holder shall survive the consummation of the transactions contemplated by this Agreement.


  11.

Governing Law.

 

  a.

Except as provided for in paragraph b below, this Agreement shall be governed by, and construed in accordance with, the laws of the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein.

 

  b.

To the extent that the provisions of this Agreement relate to the Account Assignment Agreement or any other Swiss law governed Security Document or any security or lien created thereunder, such provisions shall in all respects, including all the rights in rem aspects, be governed by and construed in accordance with the substantive laws of Switzerland, without regard to the principles of conflict of laws, and with respect to any dispute arising out of or in connection with such provisions, the jurisdiction clause contained in the Account Assignment Agreement or other relevant Swiss law governed Security Document shall apply mutatis mutandis.

 

  12.

Counterparts. This Agreement may be executed in any number of counterparts, all of which shall constitute one and the same agreement, and any party hereto may execute this Agreement by signing and delivering one or more counterparts. Delivery of an executed counterpart of this Agreement electronically or by facsimile shall be effective as delivery of an original executed counterpart of this Agreement.

 

  13.

Announcement. The Company shall file a Form 6-K announcing the terms of this Agreement and filing this Agreement as an exhibit thereto on or before 5:30 p.m. (local time in New York, New York) on the Business Day after the date of this Agreement. Following the filing of such Form 6-K the Holder shall not be deemed to be in possession of any material, non-public information of the Company.

[SIGNATURE PAGE FOLLOWS]


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

JGB (CAYMAN) PORT ELLEN LTD.
By:  

/s/ Brett Cohen

Name:   Brett Cohen
Title:   President
E-mail   Address for delivery of Notices:
OBSEVA SA
By:  

/s/ Will Brown

Name:   Will Brown
Title:   Chief Financial Officer
E-mail   Address for delivery of Notices:
OBSEVA USA INC.
By:  

/s/ Will Brown

Name:   Will Brown
Title:   Chief Financial Officer
E-mail   Address for delivery of Notices:
OBSEVA IRELAND LTD.
By:  

/s/ Fabien de Ladonchamps

Name:   Fabien de Ladonchamps
Title:   Director
E-mail   Address for delivery of Notices:
OBSEVA EUROPE B.V.
By:  

/s/ Fabien de Ladonchamps

Name:   Fabien de Ladonchamps
Title:   Chief Administrative Officer
E-mail   Address for delivery of Notices:

[Signature Page to Amendment Agreement]